Article Details
Retrieved on: 2025-09-09 18:17:18
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Regeneron Pharmaceuticals' first-in-class investigational allergen-blocking monoclonal antibodies (mAbs) met their primary endpoints in two Phase ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here